Cipher Pharmaceuticals Inc.
CPHRF
$10.35
-$0.12-1.11%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.27% | 28.91% | 51.22% | 89.17% | 114.78% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.27% | 28.91% | 51.22% | 89.17% | 114.78% |
| Cost of Revenue | -26.03% | -15.57% | 8.30% | 152.73% | 197.61% |
| Gross Profit | 15.03% | 46.25% | 67.71% | 74.04% | 95.45% |
| SG&A Expenses | -26.63% | -7.80% | 33.22% | 101.17% | 218.27% |
| Depreciation & Amortization | 1.84% | 30.04% | 80.03% | 149.62% | 529.12% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.17% | -4.02% | 31.63% | 124.89% | 240.94% |
| Operating Income | 104.04% | 175.02% | 114.90% | 29.24% | -12.39% |
| Income Before Tax | 202.98% | 979.24% | 480.81% | 2.17% | -53.08% |
| Income Tax Expenses | -80.63% | -44.37% | -18.35% | -20.42% | 38.17% |
| Earnings from Continuing Operations | 138.70% | 233.85% | 136.72% | 9.50% | -46.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 138.70% | 233.85% | 136.72% | 9.50% | -46.27% |
| EBIT | 104.04% | 175.02% | 114.90% | 29.24% | -12.39% |
| EBITDA | 59.90% | 112.30% | 103.68% | 55.36% | 37.20% |
| EPS Basic | 140.80% | 227.28% | 127.03% | 3.38% | -48.76% |
| Normalized Basic EPS | 115.02% | 309.76% | 185.92% | -11.72% | -36.87% |
| EPS Diluted | 140.43% | 226.67% | 125.22% | 4.18% | -48.52% |
| Normalized Diluted EPS | 117.28% | 314.27% | 185.92% | -12.71% | -37.70% |
| Average Basic Shares Outstanding | -0.38% | 1.83% | 3.15% | 4.83% | 4.48% |
| Average Diluted Shares Outstanding | -0.28% | 2.13% | 4.36% | 4.97% | 4.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |